Original article| Volume 54, ISSUE 9, P873-878, November 01, 2003

Download started.


Stress hormone responses to corticotropin-releasing hormone in substance abusers without severe comorbid psychiatric disease



      Preclinical data indicate a crucial role of stress in the acute effects of drugs of abuse, maintenance of self-administration, and susceptibility to relapse. Stress system activation may serve as a marker for a neurochemical dysfunction with prognostic significance in patients with addiction.


      We tested pituitary adrenocorticotrophin (ACTH) and adrenal cortisol response to ovine corticotropin-releasing hormone (oCRH) to assess the reactivity of the hypthalamic–pituitary–adrenal (HPA) axis in seven nonsubstance-abusing subjects, 31 polysubstance-abusing subjects without depressive symptoms, and seven subjects with substance abuse and depressive symptoms. No subject met diagnostic criteria for depression or other severe psychiatric disease.


      Compared with normal control subjects, substance abusers showed significantly lower ACTH and cortisol responses over the course of oCRH stimulation (p < .0001). Substance abusers with depressive symptoms showed similarly blunted responses.


      Polysubstance abusers with no past or current diagnosis of other Axis I disorders show blunted ACTH and cortisol responses to oCRH administration. The finding of an activated HPA axis in this population suggests an overlapping role of central CRH and HPA axis activation in affective disorders and substance abuse, which is likely to constitute an endocrine milieu necessary for the maintenance of addictive behavior. These data support the role of future therapeutic trials with nonpeptide CRH receptor 1 antagonists in these patients.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Beck A.T.
        • Weissman A.
        • Lester D.
        • Trexler L.
        The measurement of pessimism.
        J Consult Clin Psychol. 1974; 42: 861-865
        • Cador M.
        • Cole B.J.
        • Koob G.F.
        • Stinus L.
        • Le Moal M.
        Central administration of corticotropin releasing factor induces long-term sensitization to D-amphetamine.
        Brain Res. 1993; 606: 181-186
        • Coiro V.
        • Vescovi P.P.
        Effect of cigarette smoking on ACTH/cortisol secretion in alcoholic after short- and medium-term abstinence.
        Alcohol Clin Exp Res. 1999; 23: 1515-1518
        • Derogatis L.R.
        Administration, Scoring, and Procedures for SCL-90R. Clinical Psychometric Research, Towson, MD1983
        • De Souza E.B.
        Corticotropin-releasing factor receptors in the rat central nervous system.
        J Neurosci. 1987; 7: 88-100
        • De Souza E.B.
        • Perrin M.H.
        • Insel T.R.
        • Rivier J.
        • Vale W.W.
        • Kuhar M.J.
        Corticotropin-releasing factor receptors in rat forebrain.
        Science. 1984; 224: 1449-1451
        • Ellison C.W.
        Spiritual well-being.
        J Psychol Theol. 1983; 11: 330-340
        • Errico A.L.
        • Parsons O.A.
        • King A.C.
        • Lovallo W.R.
        Attenuated cortisol response to biobehavioral stressors in sober alcoholics.
        J Stud Alcohol. 1993; 54: 393-398
        • Gold P.
        • Loriaux D.
        • Roy A.
        • Kling M.
        • Calabrese J.
        • Kellner C.
        • et al.
        Responses to corticotrophin-releasing hormone in the hypercortisolism of depression and Cushing’s disease.
        N Engl J Med. 1986; 314: 1329-1335
        • Grigoriadis D.E.
        • Heroux J.A.
        • De Souza E.B.
        Characterization and regulation of corticotropin-releasing factor receptors in the central nervous, endocrine and immune systems.
        Ciba Found Symp. 1993; 172: 85-101
        • Grigoriadis D.E.
        • Zaczek R.
        • Pearsall D.M.
        • De Souza E.B.
        Solubilization of high affinity corticotropin-releasing factor receptors from rat brain.
        Endocrinology. 1989; 125: 3068-3077
        • Habib K.E.
        • Weld K.P.
        • Rice K.C.
        • Pushkas J.
        • Champoux M.
        • Listwak S.
        • et al.
        Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates.
        Proc Natl Acad Sci U S A. 2000; 97: 6079-6084
        • Helzer J.E.
        • Robins L.N.
        The diagnostic interview schedule.
        Soc Psychiatry Psychiatr Epidemiol. 1988; 23: 6-16
        • Kemper A.
        • Koalick F.
        • Thiele H.
        • Retzow A.
        • Rathsack R.
        • Nickel B.
        Cortisol and beta-endorphin response in alcoholics and alcohol abusers following a high naloxone dosage.
        Drug Alcohol Depend. 1990; 25: 319-326
        • Lovallo W.R.
        • Dickensheets S.L.
        • Myers D.A.
        • Thomas T.L.
        • Nixon S.J.
        Blunted stress cortisol response in abstinent alcoholic and polysubstance-abusing men.
        Alcohol Clin Exp Res. 2000; 24: 651-658
        • McLellan A.T.
        • Luborsky L.
        • Cacciola J.
        • Griffith J.
        • McGaham P.
        • O’Brien C.P.
        Guide to the Addiction Severity Index. National Institute on Drug Abuse, Treatment Research Reports, Rockville, MD1986
        • Meier C.A.
        • Biller B.M.
        Clinical and biochemical evaluation of Cushing’s syndrome.
        Endocrinol Metab Clin North Am. 1997; 26: 741-762
        • Newell-Price J.
        • Trainer P.
        • Besser M.
        • Grossman A.
        The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states.
        Endocr Rev. 1998; 19: 647-672
        • O’Toole S.M.
        • Sekula L.K.
        • Rubin R.T.
        Pituitary-adrenal cortical axis measures as predictors of sustained remission in major depression.
        Biol Psychiatry. 1997; 42: 85-89
        • Robins S.
        • Helzer J.E.
        • Cuttler L.
        • Golding E.
        National Institute of Mental Health Diagnostic Interview Schedule Version III-R. U.S. Government Printing Office, Washington, DC1988
        • Rodriguez de Fonseca F.
        • Carrera M.R.A.
        • Navarro M.
        • Koob G.F.
        • Weiss F.
        Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal.
        Science. 1997; 276: 2050-2054
        • Sarnyai Z.
        • Biro E.
        • Gardi J.
        • Vecsernyes M.
        • Julesz J.
        • Telegdy G.
        Brain corticotropin-releasing factor mediates ‘anxiety-like’ behavior induced by cocaine withdrawal in rats.
        Brain Res. 1995; 675: 89-97
        • Sarnyai Z.
        • Hohn J.
        • Szabo G.
        • Penke B.
        Critical role of endogenous corticotropin-releasing factor (CRF) in the mediation of the behavioral action of cocaine in rats.
        Life Sci. 1992; 51: 2019-2024
        • Shaham Y.
        • Erb S.
        • Leung S.
        • Buczek Y.
        • Stewart J.
        CP-154,526, a selective, non-peptide antagonist of the corticotropin-releasing factor1 receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats.
        Psychopharmacology (Berl). 1998; 137: 184-190
        • Shaham Y.
        • Erb S.
        • Stewart J.
        Stress-induced relapse to heroin and cocaine seeking in rats.
        Brain Res Brain Res Rev. 2000; 33: 13-33
        • Stine S.M.
        • Grillon C.G.
        • Morgan 3rd, C.A.
        • Kosten T.R.
        • Charney D.S.
        • Krystal J.H.
        Methadone patients exhibit increased startle and cortisol response after intravenous yohimbine.
        Psychopharmacology (Berl). 2001; 154: 274-281
        • Vale W.
        • Spiess J.
        • Rivier C.
        • Rivier J.
        Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin.
        Science. 1981; 213: 1394-1397
        • Vescovi P.P.
        • DiGennaro C.
        • Coiro V.
        Hormonal (ACTH, cortisol, beta-endorphin, and met-enkephalin) and cardiovascular responses to hyperthermic stress in chronic alcoholics.
        Alcohol Clin Exp Res. 1997; 21: 1195-1198
        • Wong M.L.
        • Webster E.L.
        • Spokes H.
        • Phu P.
        • Ehrhart-Bornstein M.
        • Bornstein S.
        • et al.
        Chronic administration of the non-peptide CRH type 1 receptor antagonist antalarmin does not blunt hypothalamic-pituitary-adrenal axis responses to acute immobilization stress.
        Life Sci. 1999; 65: PL53-PL58
        • Zobel A.W.
        • Nickel T.
        • Kunzel H.E.
        • Ackl N.
        • Sonntag A.
        • Ising M.
        • Holsboer F.
        Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression.
        J Psychiatr Res. 2000; 34: 171-181